CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Jemperli dostarlimab Endometrial cancer Active
Libtayo cemiplimab Locally advanced or metastatic NSCLC (first line) Active
Keytruda pembrolizumab Gastric or gastroesophageal junction adenocarcinoma Active
Keytruda pembrolizumab Biliary tract carcinoma Active
Doptelet avatrombopag Chronic immune thrombocytopenia (ITP) Active
TBC cabotegravir HIV-1 infection, pre-exposure prophylaxis Active
Epkinly epcoritamab Relapsed or refractory diffuse large B-cell lymphoma Active
Opdivo nivolumab Stage IIB or IIC melanoma, adjuvant Active
Bimzelx bimekizumab Ankylosing spondylitis Active
Bimzelx bimekizumab Psoriatic arthritis Active
Last Updated : May 2, 2024